Abstract
Receptors of the insulin/insulinlike growth factor (IGF) family have been implicated in the regulation of pancreatic β-cell growth and insulin secretion. The insulin receptor-related receptor (IRR) is an orphan receptor of the insulin receptor gene (Ir) subfamily. It is expressed at considerably higher levels in β cells than either insulin or IGF-1 receptors, and it has been shown to engage in heterodimer formation with insulin or IGF-1 receptors. To address whether IRR plays a physiologic role in β-cell development and regulation of insulin secretion, we have characterized mice lacking IRR and generated a combined knockout of Ir and Irr. We report that islet morphology, β-cell mass, and secretory function are not affected in IRR-deficient mice. Moreover, lack of IRR does not impair compensatory β-cell hyperplasia in insulin-resistant Ir+/− mice, nor does it affect β-cell development and function in Ir−/− mice. We conclude that glucose-stimulated insulin secretion and embryonic β-cell development occur normally in mice lacking Irr.
In its simplest formulation, diabetes results from the inability of pancreatic β cells to maintain adequate insulin levels and prevent hyperglycemia. In type 1 diabetes, β-cell failure is caused by immune mechanisms, whereas in type 2 diabetes, it results from a combination of genetic and environmental causes (6, 33). It is generally agreed that insulin resistance is the main metabolic abnormality in type 2 diabetes and that it predisposes to β-cell failure (16, 41). The mechanism by which this occurs remains obscure. Based on observations in genetically engineered mice lacking various components of the insulin/insulinlike growth factor (IGF) signaling pathway, it has been proposed that insulin and IGF receptors regulate two key processes in the life of a β cell: proliferation and hormone secretion. Kulkarni et al. showed that ablation of Ir in β cells by site-specific recombination leads to altered glucose sensing and impairs glucose tolerance (22). A similar phenotype results from generalized ablation of Irs-1, a key molecule in insulin signaling (23). These data are consistent with the model proposed by Leibiger et al., in which insulin secretion provides a positive feedback regulation of insulin gene transcription (25). On the other hand, it has been shown that ablation of Irs-2 impairs β-cell growth in mice in a strain-dependent manner (21, 48) and that this phenotype is exacerbated by Igf1r haploinsufficiency, leading Withers and coworkers to propose that IGF-1R signaling through IRS-2 is required for β-cell growth (47).
IRR is an orphan receptor of the Ir family (39) which does not bind insulin or insulinlike peptides (14, 20, 49) and can be expressed as variably spliced isoforms (12). The tissue distribution of the Irr product is more restricted than that of either Ir or Igf1r (4, 24, 32, 34, 35, 40, 42–44, 46). In the kidney, the organ with the highest levels of Irr mRNA (24, 27, 34), IRR immunoreactivity has been detected in non-A intercalated cells (4, 32). In neural tissues, Irr expression is preferentially found in colinergic neurons of rat forebrain (42, 43) and in sympathetic and sensory neurons (34), where it appears to colocalize with TrkA receptors in nerve growth factor-positive neurons (35, 42). In the stomach, Irr mRNA is found in enterocromaffin cells (44).
Irr is also expressed in pancreatic islets, where it localizes to β cells (10, 31). Hirayama et al. reported that Irr mRNA is more abundant than either Ir or Igf1r mRNA in β cells and that its protein product is preferentially expressed as unprocessed precursor (10).
The function of IRR is unknown. Holodimeric IRR expressed in NIH 3T3 cells can be activated by vanadate (14), and heterodimeric IR/IRR receptors can be activated by insulin to phosphorylate IRS-1 and IRS-2, providing proof of principle of the signaling abilities of its kinase (10, 49). Similarly, a chimeric TrkB/IRR receptor can induce mitogen-activated protein (MAP) kinase activity in PC-12 cells and promote neurite outgrowth, in contrast to IR activation, which induces proliferation (17). Because IRR has been shown to engage in heterodimer formation with both IR and IGF-1R (13, 20), it is possible that it functions by modulating IR and/or IGF-1R signaling in either a positive or negative manner (37). The latter possibility is especially appealing to explain IRR function in β cells, where hybrid IR/IRR receptors may provide a mechanism to prevent a constitutive state of insulin-induced IR phosphorylation and downregulation. It is unclear, in fact, how IR and IGF-1R may be regulated in the β cell, in view of the fact that IR is presumably exposed to high insulin concentrations in the pancreatic portal circulation and that IGF-1 has been shown to inhibit insulin secretion (50).
To address these questions, we have studied the effects of nullizygous Irr mutations on β-cell development and secretory function and generated mice lacking both Ir and Irr to study the effect of the Irr mutation in a diabetes-predisposing background.
MATERIALS AND METHODS
Gene targeting and generation of Irr knockout mice.
We used a mouse Irr cDNA as a probe to screen a mouse 129 genomic lambda library. Seven overlapping clones covering most of the Irr gene were found and subsequently mapped with several restriction enzymes. The targeting construct was made by inserting a pGK-neo cassette into the XhoI restriction site in the third coding exon of Irr. The positive-negative selection method was used, inserting the thymidine kinase gene at the end of the shorter arm of the targeting construct (Fig. 1) (26). The construct was linearized with NotI and electroporated into CJ7 embryonic stem (ES) cells. Homologous recombinants were identified by Southern blotting with appropriate 5′- and 3′-flanking probes. Four ES cell clones bearing the desired recombination events were microinjected into E3.5 blastocysts as described (1), and resulting chimeric offspring were tested for germ line transmission by back-crossing onto C57BL/6J.
RT-PCR analysis of IRR gene expression.
mRNA was isolated from kidney of Irr−/− and wild-type mice using the Micro-Fast Track 2.0 kit (Invitrogen, Carlsbad, Calif.) and employed to synthesize cDNA using a Gene Amp RNA PCR kit (Perkin-Elmer, Boston, Mass.). PCR was performed using cDNA as a template and amplification primers corresponding to the sequences of exon 2 and exon 4 of Irr (forward primer, 5′ ACT GAC TAC AGG TGC TGG ACG 3′; reverse primer, 5′ ACC AGG TCC TGT GTG GCT TGG 3′). PCR amplification conditions were as follows: 2 min at 95°C, followed by 35 cycles at 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min. The last extension cycle was carried out for 7 min. Reaction products were analyzed by agarose gel electrophoresis. The bands corresponding to the Irr mRNA product (436 bp) were excised from the gel and sequenced to confirm the mRNA identity.
Western blot analysis of IRR.
Western blot analysis was performed with membrane preparations from kidney, liver, or a 293 cell line expressing IRR under the control of a cytomegalovirus promoter. Proteins (30 μg) were separated under nonreducing conditions on a 5 to 20% polyacrylamide gradient gel at 50 A for 4 h and then transferred to a nitrocellulose membrane overnight. The membrane was blocked for 1 h with Tris-buffered saline–Triton X-100 (TBS-T) buffer supplemented with 3% milk and incubated with an antipeptide antibody raised against a synthetic 15-amino-acid peptide corresponding to a fragment of the juxtamembrane domain of IRR (sp-727, 6.6 μg/ml) for 3 h. After incubation with the second antibody (goat anti-rabbit immunoglobulin-horseradish peroxidase conjugate, 1:2,000 dilution) for 1 h and chemiluminescent detection (ECL kit; Amersham), the blot was exposed to X-ray film.
Animal production and genotyping.
Mice bearing a null Ir allele have been described in previous publications (18). Intercrosses of Irr+/− and Ir+/− mice were used to obtain mice of five genotypes: WT, Ir+/−, Irr−/−, Irr−/− Ir+/−, and Irr−/− Ir−/−. Genotyping was performed as follows. The wild-type Ir allele was detected using forward primer 5′ TCT TTG CCT GTG CTC CAC TCT 3′ and reverse primer 5′ CTG TGC ACT TCC CTG CTC ACA 3′; the null Ir allele was detected using forward primer 5′ TCT TTG CCT GTG CTC CAC TCT 3′ and reverse primer 5′ ATA TTG CTG AAG AGC TTG GCG 3′. The product of the wild-type allele was approximately 100 bp, and that of the null allele was approximately 500 bp. PCR amplification conditions were 4 min at 94°C followed by 30 cycles at 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min, and then 72°C for 7 min. The Irr mutant mice were routinely genotyped by PCR. The wild-type allele was detected using oligonucleotides 4856 and 4857, while the mutant allele was detected using oligonucleotides 3202 and 4856 (3202, 5′ CGC CTT CTT GAC GAG TTC TTC TG 3′; 4856, 5′ GTG TGT CCC TGC CCC CGA GGG 3′; 4857, 5′ TGA CAC AGC GCC AGG ACT CAT 3′). The PCR program used consisted of 94°C for 3 min followed by 35 cycles of 94°C for 1 min, 56°C for 1 min, and 72°C for 2 min, followed by a final 5-min extension at 72°C.
Phenotypic analysis.
Blood was drawn from the retroorbital sinus of anesthetized adult mice. Only male mice were used in the analysis because they are more prone to insulin resistance. Newborn mice were euthanized by CO2 followed by cervical dislocation and exsanguinated for glucose and insulin measurements. Blood glucose levels were determined using an Accucheck glucometer from Boehringer Mannheim (Mannheim, Germany). Serum insulin was measured by radioimmunoassay using a rat insulin standard (Linco Research, St. Charles, Mo.). All assays were carried out in duplicate. Each value represents the mean of two independent determinations (18).
Intraperitoneal glucose tolerance test.
Mice fasted for 16 h and were anesthetized with pentobarbital (40 mg/kg of body weight). Blood was drawn immediately prior to and 30, 60, 90, and 120 min after intraperitoneal injection of glucose (2 g/kg of body weight) (18). Glucose and insulin levels were measured as described above.
Insulin tolerance test.
Mice were fed freely and tested between 2 and 4 p.m. Mice were anesthetized with pentobarbital (40 mg/kg body of weight). Blood samples were drawn immediately prior to and 30 and 60 min after intraperitoneal injection of 0.75 U of human insulin (Sigma) per kg of body weight (0.026 mg/kg). Glucose levels were measured as described above.
Insulin secretion from isolated islets.
Islets were isolated from 6-month-old WT, Irr−/−, Irr−/− Ir+/−, and Ir+/− mice by collagenase digestion followed by centrifugation over a Histopaque gradient. Briefly, after clamping the common bile duct at its entrance to the duodenum, 3 ml of M199 medium containing 1 mg of collagenase P (Roche Molecular Biochemicals, Indianapolis, Ind.) per ml was injected into the duct. The swollen pancreas was surgically removed and incubated at 37°C for 17 min. Thereafter, 30 ml of ice-cold M199 medium containing 10% newborn calf serum (NCS) was added to stop the digestion reaction. Digested pancreata were dispersed by pipetting and rinsed twice with 30 ml of the same medium. After filtering the tissue suspension through a Spectra-mesh (408 μm; Spectrum Laboratories, Inc.), the digested tissue was resuspended in 10 ml of Histopaque and overlaid with 10 ml of M199 medium. The sample was then centrifuged at 1,700 × g for 20 min, and the islets were collected from the interface. The recovered material was washed twice with cold M199 medium, resuspended in RPMI medium containing 10% NCS and 5 mM glucose, and cultured overnight at 37°C in 5% CO2. For insulin secretion assays, islets were manually picked under a dissection microscope using a pipette, placed in ice-cold Krebs buffer (119 mM NaCl, 2.5 mM CaCl2, 1.19 mM KH2PO4, 1.19 mM Mg2SO4, 10 mM HEPES [pH 7.4], 2% bovine serum albumin, and 2.8 mM glucose) and incubated at 37°C for 15 min. At the end of the incubation period, islets were stimulated with various glucose concentrations (2.8, 5.6, 11.2, and 16.8 mM) for 1 h at 37°C. At the end of the incubation, the islets were collected by centrifugation and the supernatant was assayed for insulin content by radioimmunoassay (22).
Immunohistochemical and morphometric analysis of pancreatic islets.
Pancreata were removed from 4-day-old WT, Irr−/−, and Irr−/− Ir−/− mice and fixed overnight in Bouin's solution. Tissues were embedded in paraffin, and consecutive 5-μm sections were mounted on slides. After rehydration and permeabilization in 0.1% Triton X-100, sections were immunostained for β cells using mouse anti-insulin antibodies and for α cells using mouse antiglucagon antibodies (Sigma Chemical Co.). For quantitation of α- and β-cell area, two animals for each genotype were analyzed at postnatal day 4. For each pancreas, 10 sections were covered systematically by accumulating images from nonoverlapping fields. Images were captured with a digital camera (Nikon 950) and analyzed using the NIH Image 1.60 software as described previously (18). Results were expressed as a percentage of the total surveyed pancreatic area occupied by α and β cells.
RESULTS
Irr−/− mice do not express Irr mRNA.
To generate mice lacking IRR, a nonsense mutation was introduced in exon 3 of murine Irr by homologous recombination in mouse ES cells. The targeting strategy is shown in Fig. 1. To confirm that this mutation resulted in the generation of a null Irr allele, we performed reverse transcription (RT)-PCR amplification on mRNA isolated from kidney of WT and Irr−/− mice. Kidney was chosen as the organ with the highest levels of Irr expression (4, 24, 34). The expected PCR product of 436 bp was detected in WT mice but not in Irr−/− mice (Fig. 2). An additional PCR product of 476 bp was detected in both WT and Irr−/− mice. Sequence analysis indicated that this DNA fragment corresponds to Ir mRNA, whereas the lower band corresponds to Irr mRNA (data not shown), consistent with the notion that Irr−/− mice do not express Irr mRNA.
We next examined the expression of IRR protein using antipeptide antibody raised against a synthetic 15-amino-acid peptide corresponding to a fragment of the juxtamembrane domain of the IRRβ subunit (4). Under nonreducing conditions, a 350-kDa peptide corresponding to the heterotetrameric IRR band was detected in WT and Irr+/− mice but not in Irr−/− kidney extract (Fig. 3).These results indicate that the Irr protein product is absent in Irr−/− mice.
Phenotypic characterization of mice lacking IRR.
Irr−/− mice were born with the expected Mendelian frequency and showed no growth, morphological, or gross behavioral abnormalities (data not shown). To assess the consequences of Irr ablation on glucose metabolism, we measured whole-blood glucose and serum insulin levels in the fasting and fed states in 6-month-old WT and Irr−/− mice. No differences were detected between WT and Irr−/− mice (Table 1). Glucose tolerance tests were performed to detect subtle defects in insulin sensitivity that would not result in overt diabetes. However, glucose values following intraperitoneal glucose administration were similar in WT and Irr−/− mice (Fig. 4a). To determine whether the lack of IRR would affect metabolic control in the context of a predisposing background, we crossed Irr−/− mice with insulin-resistant Ir+/− mice (1, 19), which have been shown to develop diabetes with high frequency when crossed with mice bearing other predisposing mutations (7, 8, 18). Irr−/− Ir+/− mice showed fasting and fed glucose and insulin levels similar to those seen in Ir+/− mice (Table 1). Glucose tolerance tests indicated that Irr−/− Ir+/− mice were as glucose intolerant as Ir+/− mice, suggesting that lack of IRR does not further impair glucose metabolism (Fig. 4b). Insulin tolerance tests failed to demonstrate any difference among WT, Irr−/−, and Irr−/−Ir+/− mice (Fig. 4c). We next examined pancreatic islets by immunohistochemistry with anti-insulin antibodies. Islet mass was moderately enlarged in Ir+/− mice (Fig. 5, upper right panel). In contrast, Irr−/− mice had islet mass similar to that of WT controls. In Irr−/− Ir+/− mice, islet mass was similar to that observed in Ir+/− mice (Fig. 5, lower right panel). Morphometric analyses failed to reveal differences between islets from Irr−/− and Irr−/− Ir+/− mice (not shown).
TABLE 1.
Genotype (n) | Body wt (gm) | Glucose
|
Insulin
|
||
---|---|---|---|---|---|
Fasting | Fed | Fasting | Fed | ||
WT (15) | 35.8 ± 0.7 | 96 ± 4 | 135 ± 6 | 0.7 ± 0.2 | 2.8 ± 0.8 |
Irr−/− (20) | 36.0 ± 0.8 | 104 ± 6 | 139 ± 11 | 0.5 ± 0.1 | 3.8 ± 0.6 |
Irr+/− (16) | 34.0 ± 0.8 | 97 ± 3 | 132 ± 12 | 1.4 ± 0.4 | 8.4 ± 1.2 |
Irr−/−Ir+/− (21) | 34.5 ± 0.9 | 98 ± 5 | 134 ± 9 | 0.8 ± 0.2 | 9.6 ± 1.6 |
The data represent the mean ± SEM. Values for individual mice represent the mean of at least two separate determinations. Values for insulin are in nanograms per milliliter; values for glucose are in milligrams per decaliter.
Normal glucose-induced insulin secretion in pancreatic islets isolated from Irr−/− mice.
In view of the potential role of IRR in β-cell function, we examined glucose-induced insulin secretion in islets isolated from Irr−/− and Irr−/− Ir+/− mice and compared them with WT islets. As shown in Fig. 6, glucose induced a dose-dependent increase in insulin secretion up to a maximum of ∼20-fold over basal at 16.8 mM. Similar secretion patterns were observed in all genotypes examined, which included WT, Irr−/−, Ir+/−, and Irr−/− Ir+/− mice. These data, along with the data on in vivo glucose tolerance, are consistent with a preserved function of Irr−/− islets to secrete insulin in response to a glucose challenge.
Development of diabetes in Ir/Irr double-knockout mice.
Next, we investigated the possibility that the lack of an overt phenotype in Irr−/− mice may be due to compensation by Ir. Thus, double-knockout mice lacking both Irr and Ir were obtained and characterized. This type of analysis was limited to the immediate postnatal period, since mice lacking Ir die within a week of birth. As shown in Fig. 7, plasma glucose and insulin levels rose sharply after birth in Irr−/− Ir−/− mice, similar to Ir−/− mice (1). Double-knockout mice died of diabetic ketoacidosis within 5 days of birth. Thus, ablation of Irr did not affect the phenotype of Ir−/− mice.
Islet morphology and analysis of β-cell mass in Irr−/− and Irr−/− Ir−/− double-knockout mice.
We next examined α- and β-cell mass and islet morphology in newborn Irr and Ir Irr knockout mice to detect possible effects of the Irr mutation on embryonic development of islets. As shown in Fig. 8, islet morphology was unchanged. β-Cell mass represented ∼2.5% and α-cell mass represented ∼0.5% of total pancreatic mass in both Irr−/− and Irr−/− Ir−/− mice. These findings are consistent with the conclusion that Irr is not required for completion of islet development and early postnatal insulin secretion.
DISCUSSION
An important contribution of mice with targeted gene mutations to our understanding of the pathogenesis of insulin resistance is the notion that insulin/IGF signaling affects β-cell function in multiple ways (15). The current paradigm is that IGF-1Rs promote β-cell growth through IRS-2, whereas IRs contribute to glucose sensing through IRS-1 signaling (11, 22, 23, 25, 36, 38, 47, 48). In this model, it remains unclear how IR and IGF-1R would be protected from rapid ligand-induced internalization, given that they are exposed to very high insulin concentrations.
The presence of IRR in β cells has been demonstrated by two groups using different approaches (10, 31). IRR can potentially participate in β-cell growth and function in two possible ways: by mediating signaling of its own — as yet unknown— ligand, or by engaging in heterodimer formation with IR and/or IGF-1R (13, 20, 49). With respect to the first hypothesis, limited evidence does indeed suggest that IRR signaling in PC-12 cells is qualitatively different from IR signaling, with the former being more tightly associated to activation of MAP kinase and cellular differentiation (17), and the latter being required for cellular proliferation (28, 29). It is thus possible that IRR would have a separate role from IR and IGF-1R and that its inability to bind insulin would protect it from ligand-induced internalization. Alternatively, IRR could participate in the formation of heterodimers composed of an IRR monomer and an IR or IGF-1R monomer. It could be envisioned that such heterodimers could either affect ligand-induced internalization or potentiate signaling by determining substrate selection. A similar mechanism, whereby an orphan receptor can modulate the function of liganded receptors of the same family by engaging in heterodimer formation, has been shown for ErbB2, the orphan receptor of the epidermal growth factor family (5, 9, 30, 37, 45).
The hypothesis tested in these studies was that IRR plays a physiologic role in β cells. The data obtained for Irr−/− mice clearly disprove this hypothesis. Moreover, the failure of Irr−/− Ir+/− mice to develop either diabetes or more severe insulin resistance also indicates that IRR is not required for β-cell compensation to the mild insulin resistance caused by the Ir mutation.
The last hypothesis of our work was that Irr is required for embryonic β-cell development and that the lack of phenotype in Irr−/− mice could be explained by the compensatory actions of Ir or Igf1r. This hypothesis is based on our recent observation that combined ablation of Ir and Igf1r is compatible with normal embryonic β-cell development (Y. Kido, J. Nakae, S. Xuan, A. Efstratiadis, and D. Accili, Diabetes 49[Suppl. 1], 2000, abstr. 1066), suggesting that additional growth factor receptors contribute to β-cell growth. However, combined ablations of Ir and Irr resulted in a phenotype identical to that observed in Ir−/− mice, suggesting that embryonic β-cell development can occur in the absence of Irr.
The failure of IRR to partake in β-cell function could be related to the observation of Hirayama and coworkers that β-cell IRR is mostly expressed as an unprocessed polypeptide precursor rather than as cleaved, functionally mature α-β subunits (10). If intracellular processing of IRR occurs by a mechanism similar to IR processing, it is likely that most uncleaved precursor is retained intracellularly and is not expressed at the plasma membrane (2, 3), thus limiting the amount of functional IRR. In conclusion, the present data rule out a contribution by Irr to β-cell growth and function and indicate that lack of this orphan receptor does not affect residual IR function in insulin-resistant Ir+/− mice, consistent with the lack of a metabolic role of Irr in peripheral tissues.
ACKNOWLEDGMENTS
This work was supported by NIH grants DK58282, DK57539, and JDF 2000-893 to D.A. and by R37NS331999 to L.F.P.
We thank Jun Nakae for helpful comments on the manuscript.
REFERENCES
- 1.Accili D, Drago J, Lee E J, Johnson M D, Cool M H, Salvatore P, Asico L D, Jose P A, Taylor S I, Westphal H. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet. 1996;12:106–109. doi: 10.1038/ng0196-106. [DOI] [PubMed] [Google Scholar]
- 2.Accili D, Frapier C, Mosthaf L, McKeon C, Elbein S C, Permutt M A, Ramos E, Lander E, Ullrich A, Taylor S I. A mutation in the insulin receptor gene that impairs transport of the receptor to the plasma membrane and causes insulin-resistant diabetes. EMBO J. 1989;8:2509–2517. doi: 10.1002/j.1460-2075.1989.tb08388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Accili D, Kadowaki T, Kadowaki H, Mosthaf L, Ullrich A, Taylor S I. Immunoglobulin heavy chain-binding protein binds to misfolded mutant insulin receptors with mutations in the extracellular domain. J Biol Chem. 1992;267:586–590. [PubMed] [Google Scholar]
- 4.Bates C M, Merenmies J M, Kelly-Spratt K S, Parada L F. Insulin receptor-related receptor expression in non-A intercalated cells in the kidney. Kidney Int. 1997;52:674–681. doi: 10.1038/ki.1997.381. [DOI] [PubMed] [Google Scholar]
- 5.Beerli R R, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes N E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 1995;15:6496–6505. doi: 10.1128/mcb.15.12.6496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab. 2000;11:375–378. doi: 10.1016/s1043-2760(00)00305-2. [DOI] [PubMed] [Google Scholar]
- 7.Bruning J C, Michael M D, Winnay J N, Hayashi T, Horsch D, Accili D, Goodyear L J, Kahn C R. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell. 1998;2:559–569. doi: 10.1016/s1097-2765(00)80155-0. [DOI] [PubMed] [Google Scholar]
- 8.Bruning J C, Winnay J, Bonner W S, Taylor S I, Accili D, Kahn C R. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell. 1997;88:561–572. doi: 10.1016/s0092-8674(00)81896-6. [DOI] [PubMed] [Google Scholar]
- 9.Graus-Porta D, Beerli R R, Daly J M, Hynes N E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16:1647–1655. doi: 10.1093/emboj/16.7.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hirayama I, Tamemoto H, Yokota H, Kubo S K, Wang J, Kuwano H, Nagamachi Y, Takeuchi T, Izumi T. Insulin receptor-related receptor is expressed in pancreatic beta-cells and stimulates tyrosine phosphorylation of insulin receptor substrate-1 and -2. Diabetes. 1999;48:1237–1244. doi: 10.2337/diabetes.48.6.1237. [DOI] [PubMed] [Google Scholar]
- 11.Hugl S R, White M F, Rhodes C J. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem. 1998;273:17771–17779. doi: 10.1074/jbc.273.28.17771. [DOI] [PubMed] [Google Scholar]
- 12.Itoh N, Jobo K, Tsujimoto K, Ohta M, Kawasaki T. Two truncated forms of rat insulin receptor-related receptor. J Biol Chem. 1993;268:17983–17986. [PubMed] [Google Scholar]
- 13.Jui H Y, Accili D, Taylor S I. Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells. Biochemistry. 1996;35:14326–14330. doi: 10.1021/bi9613032. [DOI] [PubMed] [Google Scholar]
- 14.Jui H Y, Suzuki Y, Accili D, Taylor S I. Expression of a cDNA encoding the human insulin receptor-related receptor. J Biol Chem. 1994;269:22446–22452. [PubMed] [Google Scholar]
- 15.Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Investig. 2000;106:459–465. doi: 10.1172/JCI10830. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kahn B B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 1998;92:593–596. doi: 10.1016/s0092-8674(00)81125-3. [DOI] [PubMed] [Google Scholar]
- 17.Kelly-Spratt K S, Klesse L J, Merenmies J, Parada L F. A TrkB/insulin receptor-related receptor chimeric receptor induces PC12 cell differentiation and exhibits prolonged activation of mitogen-activated protein kinase. Cell Growth Differ. 1999;10:805–812. [PubMed] [Google Scholar]
- 18.Kido Y, Burks D J, Withers D, Bruning J C, Kahn C R, White M F, Accili D. Tissue-specific insulin resistance in mice with combined mutations of insulin receptor, IRS-1 and IRS-2. J Clin Investig. 2000;105:199–205. doi: 10.1172/JCI7917. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kido Y, Philippe N, Schaeffer A A, Accili D. Genetic modifiers of the insulin resistance phenotype. Diabetes. 2000;49:589–596. doi: 10.2337/diabetes.49.4.589. [DOI] [PubMed] [Google Scholar]
- 20.Kovacina K S, Roth R A. Characterization of the endogenous insulin receptor-related receptor in neuroblastomas. J Biol Chem. 1995;270:1881–1887. doi: 10.1074/jbc.270.4.1881. [DOI] [PubMed] [Google Scholar]
- 21.Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, Satoh S, Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, Nagai R, Kimura S, Akanuma Y, Taylor S I, Kadowaki T. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes. 2000;49:1880–1889. doi: 10.2337/diabetes.49.11.1880. [DOI] [PubMed] [Google Scholar]
- 22.Kulkarni R N, Bruning J C, Winnay J N, Postic C, Magnuson M A, Kahn C R. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96:329–339. doi: 10.1016/s0092-8674(00)80546-2. [DOI] [PubMed] [Google Scholar]
- 23.Kulkarni R N, Winnay J N, Daniels M, Bruning J C, Flier S N, Hanahan D, Kahn C R. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Investig. 1999;104:R69–R75. doi: 10.1172/JCI8339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kurachi H, Jobo K, Ohta M, Kawasaki T, Itoh N. A new member of the insulin receptor family, insulin receptor-related receptor, is expressed preferentially in the kidney. Biochem Biophys Res Commun. 1992;187:934–939. doi: 10.1016/0006-291x(92)91287-z. [DOI] [PubMed] [Google Scholar]
- 25.Leibiger I B, Leibiger B, Moede T, Berggren P O. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. Mol Cell. 1998;1:933–938. doi: 10.1016/s1097-2765(00)80093-3. [DOI] [PubMed] [Google Scholar]
- 26.Mansour S L, Thomas K R, Capecchi M R. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature. 1988;336:348–352. doi: 10.1038/336348a0. [DOI] [PubMed] [Google Scholar]
- 27.Mathi S K, Chan J, Watt V M. Insulin receptor-related receptor messenger ribonucleic acid: quantitative distribution and localization to subpopulations of epithelial cells in stomach and kidney. Endocrinology. 1995;136:4125–4132. doi: 10.1210/endo.136.9.7649121. [DOI] [PubMed] [Google Scholar]
- 28.Nielsen F C, Gammeltoft S. Insulin-like growth factors are mitogens for rat pheochromocytoma PC 12 cells. Biochem Biophys Res Commun. 1988;154:1018–1023. doi: 10.1016/0006-291x(88)90241-0. [DOI] [PubMed] [Google Scholar]
- 29.Ohmichi M, Pang L, Ribon V, Saltiel A R. Divergence of signaling pathways for insulin in PC-12 pheochromocytoma cells. Endocrinology. 1993;133:46–56. doi: 10.1210/endo.133.1.7686484. [DOI] [PubMed] [Google Scholar]
- 30.Olayioye M A, Neve R M, Lane H A, Hynes N E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–3167. doi: 10.1093/emboj/19.13.3159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Ozaki K. Insulin receptor-related receptor in rat islets of Langerhans. Eur J Endocrinol. 1998;139:244–247. doi: 10.1530/eje.0.1390244. [DOI] [PubMed] [Google Scholar]
- 32.Ozaki K, Takada N, Tsujimoto K, Tsuji N, Kawamura T, Muso E, Ohta M, Itoh N. Localization of insulin receptor-related receptor in the rat kidney. Kidney Int. 1997;52:694–698. doi: 10.1038/ki.1997.384. [DOI] [PubMed] [Google Scholar]
- 33.Polonsky K S, Sturis J, Bell G I. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777–783. doi: 10.1056/NEJM199603213341207. [DOI] [PubMed] [Google Scholar]
- 34.Reinhardt R R, Chin E, Zhang B, Roth R A, Bondy C A. Insulin receptor-related receptor messenger ribonucleic acid is focally expressed in sympathetic and sensory neurons and renal distal tubule cells. Endocrinology. 1993;133:3–10. doi: 10.1210/endo.133.1.8319578. [DOI] [PubMed] [Google Scholar]
- 35.Reinhardt R R, Chin E, Zhang B, Roth R A, Bondy C A. Selective coexpression of insulin receptor-related receptor (IRR) and TRK in NGF-sensitive neurons. J Neurosci. 1994;14:4674–4683. doi: 10.1523/JNEUROSCI.14-08-04674.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Rhodes C J. IGF-I and GH post-receptor signaling mechanisms for pancreatic beta- cell replication. J Mol Endocrinol. 2000;24:303–311. doi: 10.1677/jme.0.0240303. [DOI] [PubMed] [Google Scholar]
- 37.Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225. doi: 10.1016/s0092-8674(00)00114-8. [DOI] [PubMed] [Google Scholar]
- 38.Schuppin G T, Pons S, Hugl S, Aiello L P, King G L, White M, Rhodes C J. A specific increased expression of insulin receptor substrate 2 in pancreatic beta-cell lines is involved in mediating serum-stimulated beta-cell growth. Diabetes. 1998;47:1074–1085. doi: 10.2337/diabetes.47.7.1074. [DOI] [PubMed] [Google Scholar]
- 39.Shier P, Watt V M. Primary structure of a putative receptor for a ligand of the insulin family. J Biol Chem. 1989;264:14605–14608. [PubMed] [Google Scholar]
- 40.Shier P, Watt V M. Tissue-specific expression of the rat insulin receptor-related receptor gene. Mol Endocrinol. 1992;6:723–729. doi: 10.1210/mend.6.5.1603082. [DOI] [PubMed] [Google Scholar]
- 41.Taylor S I. Deconstructing type 2 diabetes. Cell. 1999;97:9–12. doi: 10.1016/s0092-8674(00)80709-6. [DOI] [PubMed] [Google Scholar]
- 42.Tsuji N, Tsujimoto K, Takada N, Ozaki K, Ohta M, Itoh N. Expression of insulin receptor-related receptor in the rat brain examined by in situ hybridization and immunohistochemistry. Brain Res Mol Brain Res. 1996;41:250–258. doi: 10.1016/0169-328x(96)00102-7. [DOI] [PubMed] [Google Scholar]
- 43.Tsujimoto K, Tsuji N, Ozaki K, Minami M, Satoh M, Itoh N. Expression of insulin receptor-related receptor mRNA in the rat brain is highly restricted to forebrain cholinergic neurons. Neurosci Lett. 1995;188:105–108. doi: 10.1016/0304-3940(95)11409-p. [DOI] [PubMed] [Google Scholar]
- 44.Tsujimoto K, Tsuji N, Ozaki K, Ohta M, Itoh N. Insulin receptor-related receptor messenger ribonucleic acid in the stomach is focally expressed in the enterochromaffin-like cells. Endocrinology. 1995;136:558–561. doi: 10.1210/endo.136.2.7835288. [DOI] [PubMed] [Google Scholar]
- 45.Tzahar E, Pinkas-Kramarski R, Moyer J D, Klapper L N, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin B J, Sela M, Andrews G C, Yarden Y. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 1997;16:4938–4950. doi: 10.1093/emboj/16.16.4938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Weiner H L, Rothman M, Miller D C, Ziff E B. Pediatric brain tumors express multiple receptor tyrosine kinases including novel cell adhesion kinases. Pediatr Neurosurg. 1996;25:64–72. doi: 10.1159/000121099. [DOI] [PubMed] [Google Scholar]
- 47.Withers D J, Burks D J, Towery H H, Altamuro S L, Flint C L, White M F. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet. 1999;23:32–40. doi: 10.1038/12631. [DOI] [PubMed] [Google Scholar]
- 48.Withers D J, Sanchez-Gutierrez J, Towery H, Burks D J, Ren J-M, Previs S, Zhang Y, Bernal D, Pons S, Shulman G I, Bonner-Weir S, White M F. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391:900–904. doi: 10.1038/36116. [DOI] [PubMed] [Google Scholar]
- 49.Zhang B, Roth R A. The insulin receptor-related receptor. Tissue expression, ligand binding specificity, and signaling capabilities. J Biol Chem. 1992;267:18320–18328. [PubMed] [Google Scholar]
- 50.Zhao A Z, Zhao H, Teague J, Fujimoto W, Beavo J A. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA. 1997;94:3223–3228. doi: 10.1073/pnas.94.7.3223. [DOI] [PMC free article] [PubMed] [Google Scholar]